Merus N.V. (MRUS) Reports Dr. Ton Logtenberg to Resign as CEO, President, Principal Financial Officer & Board Member

Go back to Merus N.V. (MRUS) Reports Dr. Ton Logtenberg to Resign as CEO, President, Principal Financial Officer & Board Member

Merus Announces Chief Executive Officer Transition

December 16, 2019 8:31 AM EST

Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer
Ton Logtenberg, Ph.D., to step down after 16 years of leadership
Transition to occur December 31, 2019

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, we, our or the Company), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced that Dr. Ton Logtenberg will step down as CEO, President, Principal Financial Officer and Director of the Company on December 31, 2019. The Merus Board of Directors has nominated Dr. Sven (Bill) Ante Lundberg, currently a... More